Verification of the Bühlmann fPELA turbo faecal elastase assay on the Binding Site Optilite benchtop analyser.


Journal

Annals of clinical biochemistry
ISSN: 1758-1001
Titre abrégé: Ann Clin Biochem
Pays: England
ID NLM: 0324055

Informations de publication

Date de publication:
01 2023
Historique:
pubmed: 27 10 2022
medline: 20 1 2023
entrez: 26 10 2022
Statut: ppublish

Résumé

Pancreatic elastase-1 (PE1) can be measured to assess exocrine activity of the pancreas. A semi-automated particle-enhanced, open-channel turbidimetric immunoassay has been introduced by Bühlmann (fPELA turbo, Bühlmann Laboratories AG, Schoenenbuch, Switzerland). Published evaluation data is lacking. We therefore verified performance of the assay on the Binding Site Optilite benchtop analyser and undertook a sample comparison with the DiaSorin PE1 assay on the Liaison. Accuracy, imprecision, lower limit of quantitation (LLoQ) and linearity of the Bühlmann fPELA turbo assay on the Binding Site Optilite analyser was ascertained. Comparison with the DiaSorin Liaison PE1 assay was also undertaken. Difference between assays was evaluated using the Wilcoxon signed-rank test and method comparison was undertaken using Spearman's rank correlation (rs), Bland-Altman and Passing-Bablok regression analyses. The fPELA turbo assay was linear between 5 and 2500 μg/g. The LLoQ was 5 µg/g. Intra- and inter-assay imprecision was <6%. There was a good agreement (rs = 0.92) and no significant bias (5.8 µg/g, The Bühlmann fPELA turbo assay performs well on the Binding Site Optilite analyser. Faecal elastase results are commutable between with Bühlmann fPELA turbo and DiaSorin Liaison PE1 assays.

Sections du résumé

BACKGROUND
Pancreatic elastase-1 (PE1) can be measured to assess exocrine activity of the pancreas. A semi-automated particle-enhanced, open-channel turbidimetric immunoassay has been introduced by Bühlmann (fPELA turbo, Bühlmann Laboratories AG, Schoenenbuch, Switzerland). Published evaluation data is lacking. We therefore verified performance of the assay on the Binding Site Optilite benchtop analyser and undertook a sample comparison with the DiaSorin PE1 assay on the Liaison.
METHODS
Accuracy, imprecision, lower limit of quantitation (LLoQ) and linearity of the Bühlmann fPELA turbo assay on the Binding Site Optilite analyser was ascertained. Comparison with the DiaSorin Liaison PE1 assay was also undertaken. Difference between assays was evaluated using the Wilcoxon signed-rank test and method comparison was undertaken using Spearman's rank correlation (rs), Bland-Altman and Passing-Bablok regression analyses.
RESULTS
The fPELA turbo assay was linear between 5 and 2500 μg/g. The LLoQ was 5 µg/g. Intra- and inter-assay imprecision was <6%. There was a good agreement (rs = 0.92) and no significant bias (5.8 µg/g,
CONCLUSION
The Bühlmann fPELA turbo assay performs well on the Binding Site Optilite analyser. Faecal elastase results are commutable between with Bühlmann fPELA turbo and DiaSorin Liaison PE1 assays.

Identifiants

pubmed: 36286495
doi: 10.1177/00045632221138025
doi:

Substances chimiques

Pancreatic Elastase EC 3.4.21.36

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

68-71

Auteurs

Simon A Handley (SA)

Department of Pathology, 34379Royal Hobart Hospital, Hobart, TAS, Australia.
School of Medicine, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.

Nikko P Dote (NP)

Department of Pathology, 34379Royal Hobart Hospital, Hobart, TAS, Australia.

Troy Wanandy (T)

School of Medicine, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
Department of Clinical Immunology and Allergy, 34379Royal Hobart Hospital, Hobart, TAS, Australia.

Louise Prentice (L)

Department of Pathology, 34379Royal Hobart Hospital, Hobart, TAS, Australia.
School of Medicine, Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH